BMC Cancer

Table 1 Association of ALDH1 status with clinicopathological charateristics, stratified by age*.

From: Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer

Characteristic	Patients < 65 years					Patients > 65 years
	ALDH1 negative		ALDH1 positive			ALDH1 negative		ALDH1 positive
	N	%	N	%	P	N	%	N	%	P
Grade					0.02					0.79
I	19	17.3	18	8.5		11	12.9	13	16.2
II	58	52.7	103	48.6		44	51.8	38	47.5
III	33	30.0	91	42.9		30	35.3	29	36.2
Histological type					0.42					0.20
Ductal	103	92.8	191	90.1		72	84.7	73	91.2
Lobular	8	7.2	21	9.9		13	15.3	7	8.7
Tumor size					0.34					0.55
T1	45	40.2	74	36.1		27	31.0	24	31.6
T2	57	50.9	101	49.3		48	55.2	37	48.7
T3/4	10	8.9	30	14.6		12	13.8	15	19.7
Nodal status					0.02					0.71
Negative	69	62.2	101	47.9		46	56.1	46	59.0
Positive	42	37.8	110	52.1		36	43.9	32	41.0
ER status					0.61					0.01
Negative	43	41.0	91	44.0		16	19.0	30	38.0
Positive	62	59.0	116	56.0		68	81.0	49	62.0
PgR status					0.77					0.08
Negative	48	47.1	84	40.6		26	31.3	35	44.9
Positive	54	52.9	123	59.4		57	68.7	43	55.1
HER2 status					0.99					0.80
Negative	67	87.0	153	86.9		61	93.8	64	92.8
Positive	10	13.0	23	13.1		4	6.2	5	7.2

*Missing data not shown.
Abbreviations: N number of patients; ALDH1 aldehyde dehydrogenase 1; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com